Absorption of sustained-release and plain papaverine in man.
The concentrations of papaverine in the plasma of healthy volunteers were determined by a GLC-method both after single and repeated oral doses of plain and sustained-release drug formulation. In both experiments the AUC-value after the sustained-release drug form was significantly lower than after the plain papaverine and no maintenance of plasma levels for 12 hours after the sustained-release drug form was observed. Our work demonstrates that the systemic availability or papaverine can be markedly affected by product formulation.
D000328:Adult; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D010208:Papaverine / Q000008:administration & dosage / Q000378:metabolism*; D013997:Time Factors
D003692:Delayed-Action Preparations; D010208:Papaverine